Mazor Robotics (NASDAQ:MZOR) and Liquidia Technologies (NASDAQ:LQDA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, profitability, earnings and analyst recommendations.
This table compares Mazor Robotics and Liquidia Technologies’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings for Mazor Robotics and Liquidia Technologies, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Mazor Robotics currently has a consensus target price of $51.67, indicating a potential downside of 11.27%. Liquidia Technologies has a consensus target price of $31.75, indicating a potential upside of 62.74%. Given Liquidia Technologies’ stronger consensus rating and higher probable upside, analysts plainly believe Liquidia Technologies is more favorable than Mazor Robotics.
Institutional and Insider Ownership
34.1% of Mazor Robotics shares are owned by institutional investors. Comparatively, 20.3% of Liquidia Technologies shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Mazor Robotics and Liquidia Technologies’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Mazor Robotics||$64.95 million||23.61||-$12.41 million||($0.50)||-116.46|
Liquidia Technologies has lower revenue, but higher earnings than Mazor Robotics.
Liquidia Technologies beats Mazor Robotics on 6 of the 8 factors compared between the two stocks.
About Mazor Robotics
Mazor Robotics Ltd., together with its subsidiaries, engages in the development, production, and marketing of medical devices for supporting surgical procedures in the fields of orthopedics and neurosurgery in the United States and internationally. It operates in the field of computer assisted surgery that enable the use of surgical instruments with high precision and minimal invasiveness and that simplifies complex surgical procedures. The company's surgical robotic-guidance systems and complementary products are used to conduct spine and brain procedures in an accurate and secure manner. It also offers Mazor X, a renaissance system and its accessories are used in spine surgeries, including fusion, correction of spinal deformities, biopsy collection, tumor excision, and cement augmentations. The company was formerly known as Mazor Surgical Technologies Ltd. and changed its name to Mazor Robotics Ltd. in 2010. Mazor Robotics Ltd. was founded in 2000 and is based in Caesarea, Israel.
About Liquidia Technologies
Liquidia Technologies, Inc. is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. PRINT technology is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. The collaborates with leading pharmaceutical companies to apply its PRINT technology across a wide range of therapeutic areas, molecule types and routes of administration. Liquidia Technologies was founded in 2004 and is headquartered in Durham, NC.
Receive News & Ratings for Mazor Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics and related companies with MarketBeat.com's FREE daily email newsletter.